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Summary
Objective: First, to assess the clinical effectiveness of hylan G-F 20 in an appropriate care treatment regimen (as defined by the American
College of Rheumatology (ACR) 1995 guidelines) as measured by validated disease-specific outcomes and health-related quality of life
endpoints for patients with osteoarthritis (OA) of the knee. Second, to utilize the measures of effectiveness and costs in an economic
evaluation (see accompanying manuscript).
Design: A total of 255 patients with OA of the knee were enrolled by rheumatologists or orthopedic surgeons into a prospective, randomized,
open-label, 1-year, multi-centred trial, conducted in Canada. Patients were randomized to ‘Appropriate care with hylan G-F 20’ (AC+H) or
‘Appropriate care without hylan G-F 20’ (AC). Data were collected at clinic visits (baseline, 12 months) and by telephone (1, 2, 4, 6, 8, 10,
and 12 months).
Results: The AC+H group was superior to the AC group for all primary (% reduction in mean Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain scale: 38% vs 13%, P=0.0001) and secondary effectiveness outcome measures. These differences
were all statistically significant and exceeded the 20% difference between groups set a priori by the investigators as the minimum clinically
important difference. Health-related quality of life improvements in the AC+H group were statistically superior for the WOMAC pain, stiffness
and physical function (all P<0.0001), the SF-36 aggregate physical component (P<0.0001) and the Health Utilities Index Mark 3 (HUI3)
overall health utility score (P<0.0001). Safety (adverse events and patient global assessments of side effects) differences favoured the
AC+H group.
Conclusion: The data presented here indicate that the provision to patients with knee OA of viscosupplementation with hylan G-F 20 within
an appropriate care treatment regimen provides benefits in the knee, overall health and health related quality of life at reduced levels of
co-therapy and systemic adverse reactions. © 2002 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All
rights reserved.
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Osteoarthritis (OA) is a common, degenerative musculo-
skeletal condition which consistently challenges the prac-
tising clinician and adds substantial burden to health care
budgets1,2. The increased prevalence of OA with aging,
coupled to the demographics of aging populations, make
OA a high priority health care problem3. OA is a leading
cause of severe activity limitations and disability, with
indirect costs to society, which can far exceed its direct
medical costs4.
Guidelines for managing the symptoms of knee OA are
available from various sources5. The goal of therapy is to
control pain and maintain function. Weight control, physical
therapy and simple analgesics such as acetaminophen, are
suggested as first-line tools for patient management to
minimize the need for higher risk treatments such as
non-steroidal antiinflammatory drugs (NSAIDs) or surgery.
NSAIDs continue to be a widely used medical therapy in
response to patient demands for symptomatic improve-
ment. In the United States alone, there are an estimated
56 000 hospitalizations and 8800 deaths each year among
OA patients, attributed to NSAID treatment6.
Viscosupplementation is a new therapy for the treatment
of knee OA based on the replacement of synovial fluid by
intraarticular injection of viscoelastic solutions containing
hyaluronan or its derivatives7. Hylan G-F 20 (Synvisc®
Genzyme Corporation, Cambridge MA U.S.A.) is one of the
viscosupplementation products approved for marketing in
Canada since 1992 and the United States since 1997 after
public review of the data by a Food and Drug Administration
(FDA) advisory panel8. A recent systematic review of the
randomized controlled trial (RCT) data on viscosupplemen-
tation concluded, that despite mixed results, the overall
data support the efficacy of viscosupplementation9. While
some physicians continue to question the efficacy of hylan
G-F 20, the reality is that hylan G-F 20 is an approved
treatment in Canada, the U.S.A., and most other countries.
Furthermore, the recently revised guidelines published by
the American College of Rheumatology (ACR) now include
viscosupplementation in the treatment paradigm for knee
OA, thus establishing it as a standard therapy10.
Considering the limited resources available for health
care, it is important to consider how incorporating the new
technology affects patient outcomes and health care
expenditures. A randomized, controlled trial of health out-
comes was specifically designed to determine the incre-
mental effectiveness, cost-effectiveness and cost-utility of
making viscosupplementation with hylan G-F 20 available
as part of an appropriate care paradigm for treating patients
with knee OA. The study utilized a pragmatic design to
maintain a real world scenario, and therefore measured
effectiveness rather than efficacy11–14. That is, rather than
asking the question of whether the treatment is efficacious
compared to placebo, the trial sought to determine whether
the treatment was effective under real world conditions.
The Canadian Guidelines for Economic Evaluation of
Pharmaceuticals state: ‘Ideally, pharmacoeconomic studies
should report on drug effectiveness rather than efficacy’15.
For this reason the trial design minimized protocol-driven
interventions and the comparator arm did not include
placebo injections. Effectiveness includes all aspects of a
treatment that add or detract from its success, including
efficacy, patient compliance and satisfaction, safety, and
positive or negative interactions with other concurrent
treatments.The availability of a safe and effective local therapy for
managing a localized condition such as knee OA might
offer important health care benefits. The clinical results and
health-related quality of life (HRQOL) outcomes for this trial
are reported here, with the economic results separately
reported in an accompanying manuscript16.Materials and methods
STUDY MANAGEMENT
The study was funded jointly by Biomatrix, Inc and
Rhoˆne-Poulenc Rorer Canada Inc. Innovus Research Inc.,
an independent contract research organization (CRO), was
contracted to manage the study. An independent Steering
Committee was assembled with the responsibility to design
the study, develop the analysis plan, resolve methodologi-
cal issues that arose throughout the study, and interpret
and disseminate study results. The Committee consisted of
five academics, one representative from each of the two
sponsoring companies and one representative from the
CRO. The Steering Committee was deliberately structured
to be dominated by the five independent academics on the
Committee. The Steering Committee actively dealt with all
scientific questions that arose throughout the course of the
study, and did so blinded to implications. The contractual
arrangement gave the investigators unrestricted rights to
publish the study results.PATIENTS
Patients were enrolled between April and December
1997, at 14 sites across Canada (10 rheumatologists, four
orthopedic surgeons). The study protocol and informed
consent form were approved by the relevant Ethics
Committees for the sites. Informed consent was obtained
from each patient.
Patients with age greater than 40 years, were required to
have a primary diagnosis of radiologically verified OA in the
study knee (knee most symptomatic or with the most
predominant musculoskeletal problem), to be symptomatic
[visual analogue scale total pain score greater than
175 mm of 500 mm on the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) pain scale]
despite prior treatment with acetaminophen or NSAIDS at
any point prior to the study, to be ambulatory and willing to
participate and sign informed consent. Patients with Grade
IV17 radiologic changes according to the clinical investi-
gators were excluded. Other exclusion criteria included
patients with inflammatory arthropathies, a tense effusion in
the study knee at baseline, chondrocalcinosis or those with
a severe varus or valgus deformity in the study knee. In
addition, patients were excluded if they had received a
steroid injection in the study knee during the prior 3 months,
if they had prior viscosupplementation therapy, if they had
isolated patellofemoral OA or any uncontrolled morbidity,
particularly morbidity in any joint which would impede
measurements in the study knee.TRIAL DESIGN
This was a multicentre, 1-year, prospective, randomized,
open-label study. Patients were randomized to either
‘appropriate care with hylan G-F 20’ (AC+H) or to ‘appro-
priate care without hylan G-F 20’ (AC). The AC group only
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other viscosupplementation products were not allowed.
Appropriate care was the preferred management strategy
of a treating physician who was encouraged to follow the
Guidelines for the Medical Management of Osteoarthritis of
the Knee proposed by the ACR5. Appropriate care could
include medications such as analgesics, NSAIDs, corticos-
teroid injections, supportive measures such as education
and counseling, weight loss, joint rest, application of heat or
ice, and use of devices, physical therapy, arthroscopy, and
total joint replacement.
Hylan G-F 20 is administered as a series of 3 intra-
articular injections at intervals of 1 week. The contralateral
knee could also be treated with hylan G-F 20, and patients
could receive subsequent treatments to either or both
knees as required.
Computer-generated randomization was designed to
be balanced (1:1 allocation ratio) within each site.
Randomization within site was blocked, but the block size
was randomly assigned as blocks of 2 or 4, with the
additional constraint that blocking was balanced for the first
12 patients. Additional patients exceeding the first block of
12, were randomly allocated in blocks of 2. The allocation
scheme was concealed from all clinical sites. Central
randomization was used whereby the site telephoned
the CRO, provided the patient’s initials, and received
the patient’s identification (ID) number and treatment
allocation.
Patients were assessed at the site during the baseline
visit and the 12-month termination visit. Patients random-
ized to AC+H returned to the site for 2 consecutive weeks
after baseline for the remaining hylan G-F 20 injections.
These were the only site visits required by the protocol.
Structured telephone interviews of the patients in both
treatment groups were conducted by the CRO at months 1,
2, 4, 6, 8, 10, and 12. The 12-month termination visit was
included for patient assessment by the investigator and for
measuring change since baseline. Patients returned to the
physician as required for clinical deterioration, treatment
of adverse events, change in medication, or additional
treatment with hylan G-F 20 if required.
Patient demographics, appropriate care treatment for
knee OA, treatment for overall OA, concomitant medi-
cations, and patient self-administered questionnaires were
collected at the baseline visit. The same information was
collected during the telephone interviews, with the addition
of pill counts performed by the patient, medication dosage
and duration, adverse events, health care resources, and
whether the health care resource was related to OA. The
patients kept a diary to keep track of this information, and
their content was provided to the telephone interviewer at
each telephone interview. During the telephone interviews,
the patient referred to the self-administered questionnaire
and provided his/her answers to the telephone interviewer.
To blind the patient to his/her previous answers to the same
questions, s/he was instructed not to record the answers,
and the questionnaire was laminated with plastic to make if
difficult if someone tried to do so. Although the question-
naires were completed originally at the baseline visit and
then during telephone interviews, a study comparing the
completion of the WOMAC Likert 3.0 questionnaire at the
physician’s office to completion over the telephone found
that differences between the modes of administration did
not reach statistical significance18. Information collected
during the telephone interviews (with the exception of the
questionnaires) was compared to the patient’s medical
chart during monitoring visits and differences wereresolved. The investigator reviewed the adverse events for
possible attribution to study interventions.OUTCOMES
The primary measure of effectiveness was the mean
change in the WOMAC Likert 3.0 pain score in the study
knee from baseline to termination. The WOMAC is a
self-administered disease-specific HRQOL instrument that
asked the patient questions concerning his/her study
knee19. The WOMAC Likert 3.0 provides scores for three
subscales: pain, stiffness, and physical functioning, and an
aggregate total score.
There were also measures of secondary effectiveness.
Two of the secondary effectiveness measures were the
percent of patients improved at termination since baseline
using different combinations of the WOMAC Likert 3.0
subscales as follows: (1) at least 20% improvement since
baseline in the WOMAC pain score in the study knee; (2) at
least 20% improvement since baseline in the WOMAC pain
score in the study knee and either 20% improvement in
function score or stiffness score. A 20% difference between
treatment groups for the primary and secondary measures
of effectiveness was established a priori by the Steering
Committee as the minimum clinically important difference,
in part based on previous research20. Other secondary
effectiveness measures were the patient global assess-
ment of effectiveness for (1) OA in study knee; (2) OA in all
joints, and (3) overall health.
HRQOL was measured using three instruments:
disease-specific HRQOL using the WOMAC; general
HRQOL using the Short Form 36 (SF-36)21, and
preference-based HRQOL using the Health Utilities Index
Mark 3 (HUI3)22. The SF-36 provides two composite
scales: aggregate physical component and aggregate
mental component. The HUI3 provides an overall multi-
attribute utility score (min: −0.36, death: 0, max: 1). The
overall utility score is the preference or worth assigned to a
particular health status on an interval scale where 0 repre-
sents death and 1 represents perfect health. States worse
than death can take on negative scores.
Safety was measured in two ways during the course of
the study. The first method was by asking patients to report
adverse events during each telephone interview and then
having the clinical site review the adverse events. The
second method of measuring safety was by asking patients
to complete global assessments of side effects. Global
assessments were measured in two ways: throughout the
study at baseline and at each telephone interview recall-
ing the past 4 weeks; and once during the 12-month
termination visit recalling the time period since the baseline
visit.STATISTICS
The sample size was calculated to detect a 20% differ-
ence between treatment groups in the primary effective-
ness measure. Using a power of 90% and =0.05, the
required sample size was 94 patients per group, for a total
of 188 patients. The final total sample size required was
252 patients, to accommodate a 20% predicted dropout
rate over 1 year and to accommodate stratification by site
(15 sites).
All patients enrolled in the study were included in the
intent-to-treat (ITT) group for all analyses. However, if a
patient in the AC group violated the protocol by receiving
hylan G-F 20 treatment, the patient was treated as a
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were not included in the analyses. These patients were
classified as crossovers, and their data following the hylan
G-F 20 treatment were imputed as was done for all drop-
outs. This was necessary to ensure the analysis was
consistent with a comparison of appropriate care in a world
with hylan G-F 20 to appropriate care in a world without
hylan G-F 20.
Two models were used for the statistical analyses, and
results for the first model are provided. The first model
adjusted for design variables (baseline value of the variable
being analysed, site, blocking by site, BMI, Baseline
WOMAC aggregate score), and the second model adjusted
for design variables and potentially clinically important
differences (as judged by the clinical principal investi-
gator while blinded to treatment allocation) between the
treatment groups at baseline.
An analysis of covariance (ANCOVA) was used for the
primary effectiveness analysis and the HRQOL analysis. A
generalized linear model was performed for analysis of
patients improved. A logistic analysis was undertaken for
the patient global assessment of side effects and effective-
ness. A nested analysis that incorporates the number of
events per patient was used to compare the number of
gastrointestinal (GI) adverse events.
The hot deck method23 was utilized to impute data for
the primary and secondary effectiveness of patient
improved. Dropout patients were matched with a patient
who completed the study. The matched patient was ran-
domly selected from the group of patients who matched the
dropout patient on criteria deemed most relevant in predict-
ing primary effectiveness. The Last Observation Carried
Forward (LOCF) imputation technique was performed to
compare to the hot deck method.ResultsPATIENT CHARACTERISTICS
A total of 255 patients were enrolled, 127 patients
randomized to AC+H and 128 to AC (Fig. 1). The central
randomization process was audited to ensure that the
randomization schedule was implemented properly. There
were more dropout patients in the AC group (21) than the
AC+H group (3) (P=0.001). Of the 21 patients who
dropped out of the AC group, the main two reasons were
that the patients wanted hylan G-F 20 (eight patients) and
that the patients were unwilling to continue (eight patients).
As shown in Fig. 1, eight patients randomized to AC
received hylan G-F 20 (protocol violators/crossovers), and
one patient in the AC+H group did not receive hylan G-F 20
(protocol violator/crossover). The patient changed their
mind after being randomized to receive hylan G-F 20.
Eighteen of the 24 patients (75%) who dropped out, did so
before Month 4. Of the 24 patients who dropped out, four
continued to have data collected during the remainder of
the study, however, the data were not used in the analyses.
Because these four patients violated the protocol by receiv-
ing hylan G-F 20 treatment despite being randomized to AC
without hylan G-F 20, their data after the hylan G-F 20
injection were not included in the analyses.
Demographic and OA status data are presented in Table
I. Greater than 79% of patients in both groups had received
previous acetaminophen and NSAID treatment for OA in
their knee(s). Although Grade IV OA in the study knee as
determined at the sites by the investigators at enrollmentwas an exclusion criterion, 20% of patients in the AC+H
group and 33% of patients in AC had grade IV OA as
subsequently determined by central radiologic grading.
Greater than 84% of patients in both groups had OA in the
other knee, and greater than 68% of patients in both groups
had other joints affected.KNEE OA TREATMENT
Table II lists knee OA and overall OA treatment. All
patients except one in the AC+H group had at least one
course of hylan G-F 20 in their study knee, and 53 (42%)
had at least 1 course in their other knee. Forty-eight
patients (38%) in the AC+H group received a second
course in the study knee, three patients (2%) received a
third course in their study knee, and 20 patients (16%)
received a second course in their other knee (data not
shown in Table II). There were more patients in the AC
group who reported corticosteroid injection(s) in the study
knee (89 vs 18) or the other knee (35 vs 8) (both
P<0.0001). There were more corticosteroid injections in the
AC group in the study knee (149 vs 27) and the other knee
(51 vs 14). There were more patients in the AC group taking
NSAIDs for any knee (P=0.0062), and other medications
for any knee (P=0.0216). Other medications included
medications such as antiinflammatories, neuralgia therapy,
opioid analgesics and vitamins. There were seven arthro-
scopies and four total knee replacements in the AC group
compared to one arthroscopy and two total knee replace-
ments in the AC+H group. Despite these reductions in the
use of medication for the study knee, there was no signifi-
cant difference between the groups in the utilization of
concomitant medications for overall OA (Table II).
The other treatments, not listed in Table II, that were
used most often in both groups were exercise, physio-
therapy, walking, water exercises, and assistive devices
such as bandages, canes, knee braces, bath bars, and
orthotics. There were too many details to provide the
other treatments and assistive devices results in Table II.
However, the cost results summarized in the accompany-
ing economic manuscript indicate that the annual cost per
patient for other therapy was $5 in the AC+H group versus
$16 in the AC group. The annual cost per patient for
assistive devices was $237 in the AC+H group versus
$305 in the AC group16.EFFECTIVENESS
Table III provides the primary and secondary effective-
ness results. The AC+H group was superior to the AC
group for all primary and secondary effectiveness
measures. These differences were all statistically signifi-
cant and exceeded the 20% minimum clinically important
difference. The AC+H group experienced a 25% greater
improvement in the WOMAC pain score in the study knee
from baseline to termination (P=0.0001). The AC+H group
had a larger percent of patients who improved by at least
20% (P=0.0001). The primary and secondary effectiveness
analyses yielded similar results for model 2 (data not
shown). Imputation using LOCF did not change the results.
The AC+H group experienced 26% greater improvement in
the WOMAC pain score, and a 30% greater improvement
in percent of patients who improved by at least 20% in
WOMAC pain. The AC+H group also did better on the
patient global assessments of effectiveness for OA in the
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(P<0.05).
Figure 2 displays the mean WOMAC pain score at each
time point during the study year. The patients in the AC+H
group had a greater reduction in the WOMAC pain score
over the full study year compared to the AC group
(P=0.0001).HEALTH-RELATED QUALITY OF LIFE
Table IV provides the baseline, Month 12, change, and
change as a % of baseline for the three HRQOL outcome
measures. For all three WOMAC subscales, the SF-36
aggregate physical component, and the HUI3 overall health
utility score, the AC+H group was statistically significantly
superior (P<0.0001). For all cases in the WOMAC and
SF-36, the difference between groups was greater than
20% except for the SF-36 aggregate physical component
where the difference between groups was 19%.Fig. 1. Trial profile.SAFETY AND TOLERABILITY
Adverse events were reported by 96% of patients (1114
events) in the AC+H group and 90% of patients (1026) in
the AC group (not compared statistically). There was one
serious adverse event in the AC group (patient presented to
the emergency room with a gastro-duodenal ulcer) listed by
the investigator as remotely related to appropriate care.
Intraarticular injection of hylan G-F 20 is occasionally
accompanied by pain, swelling, or effusion in the treated
knee. A local adverse event was defined during the analysis
as any emergent signs or symptoms occurring in the knee.
The local adverse events were subdivided into those occur-
ring within 48 hours of a hylan G-F 20 injection and those
occurring at any other time. There were 82 local adverse
events (in 38 patients) that occurred within 48 hours of a
hylan G-F 20 injection in the AC+H group. Of these 82 local
adverse events, one was reported as related to osteoarthri-
tis, nine were reported as not related to hylan G-F 20, 15
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hylan G-F 20, and 57 related to the injection procedure.
The occurrence of GI adverse events was lower in the
AC+H group for total GI events (109 vs 140 events,
P=0.0439), and GI events attributed to AC (25 vs 62
events, P=0.0001), and for total severe GI events (26 vs
53, P=0.0033), and severe GI events attributed to AC (5 vs
22, P=0.0024). Medications taken for side effects of OA
treatment were collected. Thirty-nine patients in the AC
group were taking medications for the gastrointestinal tract
compared to 21 patients in the AC+H group (P=0.0057).
For the global assessments of side effects for the time
period since baseline, 62% (79/127) of AC+H patients
experienced no side effects compared to 41% (52/128) of
AC patients (P=0.0100). The global assessments of side
effects (combined mild, moderate or severe) performed at
baseline and months 1, 2, 4, 6, 8, 10 and 12 are illustrated
in Fig. 3. Fewer patients in the AC+H group (52%; 64/124)experienced side effects at Month 12 than patients in the
AC group (68%; 73/107) (P=0.0116).Table I
Demographic information and osteoarthritis status
Demographics, f (percent of n)* AC+H
(n=127)
AC
(n=128)
Age in years, mean (S.D.) 62.6 (9.4) 63.5 (10.5)
Sex
Female 86 (68%) 93 (73%)
Body mass index (kg/m2), mean (S.D.) 32.1 (8.0) 32.9 (7.2)
OA status
Duration (years) of OA symptoms
Study knee, mean (S.D.) 9.0 (9.5) 9.9 (9.7)
Other knee, mean (S.D.) 7.4 (8.8) 8.3 (9.3)
Previous therapy for OA of the knee(s)
Acetaminophen 100 (79%) 109 (85%)
NSAIDs 120 (94%) 110 (86%)
Prior surgery, study knee 40 (31%) 39 (30%)
Prior surgery, other knee 27 (21%) 23 (18%)
Radiology grading within 1 year (central grading )
Not reported 0 (0%) 1 (1%)
Grade 0 4 (3%) 4 (3%)
Grade I 17 (13%) 11 (9%)
Grade II 32 (25%) 33 (26%)
Grade III 49 (39%) 37 (29%)
Grade IV 25 (20%) 42 (33%)
OA at baseline
Other knee affected 109 (86%) 108 (84%)
Any other joints affected 95 (75%) 87 (68%)
Patient global assessment of OA in study knee at baseline
Not reported 0 (0%) 1 (1%)
Very good 0 (0%) 0 (0%)
Good 2 (2%) 1 (1%)
Fair 44 (35%) 31 (24%)
Poor 58 (46%) 57 (45%)
Very poor 23 (18%) 38 (30%)
Patients global assessment of OA in all joints at baseline
Not reported 1 (1%) 2 (2%)
Very good 1 (1%) 2 (2%)
Good 9 (7%) 5 (4%)
Fair 54 (43%) 44 (34%)
Poor 47 (37%) 49 (38%)
Very poor 15 (12%) 26 (20%)
WOMAC pain subscale score (0–20), mean (S.D.) 11.4 (2.7) 11.9 (2.9)
*f is frequency, n is sample size. Not all percentages sum to 100 due to rounding.
†Radiology grading is based on central grading, which may have differed from the site investigator’s
determination for patient eligibility.
OA=osteoarthritis; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; AC+H=
Appropriate Care+hylan G-F 20; AC=Appropriate Care.Discussion
This report details the clinical results of a prospective,
randomized, effectiveness/health outcomes trial evaluating
the incremental value of making a new treatment modality,
viscosupplementation with hylan G-F 20, available for the
treatment of patients with knee OA. All of the clinical
outcomes measured provided consistent results favoring
the group receiving AC+H. The difference between the
groups was clinically important and statistically significant
using a disease-specific instrument (WOMAC 3.0), a
generic HRQOL instrument (SF-36), a preference based
HRQOL instrument (HUI3) and global evaluations by the
patient of OA in the study knee, overall OA, and overall
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Knee osteoarthritis treatment and overall osteoarthritis treatment
Treatment, f (percent of n)* AC+H
(n=127)
AC
(n=128)
P-value
Number of patients reporting hylan G-F 20 course(s)
Study knee 126 (99%) 6 (5%)
Other knee 53 (42%) 0 (0%)
Number of patients reporting corticosteroid injection(s)
Study knee 18 (14%) 89 (70%) <0.0001
Other knee 8 (6%) 35 (27%) <0.0001
Number of patients reporting arthroscopy
Study knee 1 (1%) 5 (4%)
Other knee 0 (0%) 2 (2%)
Number of patients reporting total knee replacement (TKR)
Study knee 1 (1%) 3 (2%)
Other knee 1 (1%) 1 (1%)
Number of patients reporting medication for any knee
Analgesic (oral) 84 (66%) 96 (75%) 0.1158
NSAID (oral) 82 (65%) 101 (79%) 0.0062
Alternative therapy 41 (32%) 44 (34%) 0.5501
Analgesic (topical) 20 (16%) 24 (19%) 0.6996
Other 13 (10%) 25 (20%) 0.0216
Number of patients reporting medications for overall osteoarthritis‡
Musculoskeletal 16 (13%) 15 (12%)
CNS 15 (12%) 12 (9%)
Minerals and vitamins 1 (1%) 1 (1%)
Anti-infectives 1 (1%) 0 (0%)
Other 5 (4%) 10 (8%)
*f is frequency, n is sample size.
†P-value results from Model 1 adjusting for design variables.
‡If a patient was taking the same medication for knee osteoarthritis and osteoarthritis in other joints, it was
included in knee osteoarthritis.
NSAIDs=non-steroidal antiinflammatory drugs; CNS=central nervous system: AC+H=Appropriate Care+
hylan G-F 20; AC=Appropriate Care.Table III
Primary effectiveness and secondary effectiveness results
AC+H
(n=127)
AC
(n=128)
[(AC+H)−
(AC)]
P-value*
Primary effectiveness n=127 n=127
Change from baseline to termination in WOMAC pain, mean (S.D.) −4.4 (3.9) −1.8 (3.8) −2.6 0.0001
Change as a % of baseline, mean (S.D.) −38.4 (34.4) −13.3 (39.9) −25.07 <0.0001
Secondary effectiveness f (percent of n)† n=127 n=127
Patients improved at termination since baseline:
WOMAC pain 87 (69%) 51 (40%) 29% 0.0001
WOMAC pain and either stiffness or physical functioning 79 (62%) 45 (35%) 27% 0.0001
Patients global assessment of change since baseline
(improved slightly, moderately, or markedly):
OA in study knee 93 (73%) 35 (27%) 46% <0.0001
OA in all joints 48 (38%) 22 (17%) 21% 0.0011
Overall health 48 (38%) 21 (16%) 22% 0.0010
Patients global assessment at month 12 over the past 4 weeks
(fair, good, or very good): n=124 n=107
OA in study knee 94 (76%) 46 (43%) 33% <0.0001
OA in all joints 88 (71%) 45 (42%) 29% <0.0001
Overall health 118 (95%) 91 (85%) 10% 0.0115
*P-value results from Model 1 adjusting for design variables. The results were similar for model 2 adjusting for design variables and
potentially clinically important differences at baseline.
†f is frequency, n is sample size. The sample size is indicated in the table heading unless otherwise indicated in the table.
OA=osteoarthritis; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; AC+H=Appropriate Care+hylan G-F 20;
AC=Appropriate Care.health. These data do not address the continuing debate
regarding the relative contribution of the intraarticular pro-
cedure and the material injected into the knee. However,they clearly demonstrate that making viscosupplementation
available as part of an AC treatment regimen results in
clinically important improvement to patients with knee OA.
Osteoarthritis and Cartilage Vol. 10, No. 7 513Fi
g.
2.
W
O
M
AC
m
e
a
n
pa
in
su
bs
ca
le
sc
o
re
by
m
o
n
th
.W
O
M
AC
=
W
e
st
er
n
O
nt
ar
io
a
n
d
M
cM
as
te
rU
ni
ve
rs
itie
s
O
st
eo
ar
th
rit
is
In
de
x.
514 J.-P. Raynauld et al.: Effectiveness of hylan G-F 20 for knee OATable IV
Mean change since baseline in WOMAC, SF-36 and HUI
Baseline Month 12 Change
(month 12–
baseline)*
Change as a %
of baseline
P-value† for
comparison
at month 12
WOMAC‡ subscales, mean (S.D.)
Pain (min: 0; max: 20)
AC+H n=127 n=127
11.35 (2.71) 6.94 (3.97) −4.41 (3.88) −38.41 (34.39) <0.0001
AC n=127 n=127
11.94 (2.89) 10.10 (4.24) −1.83 (3.83) −13.34 (39.86)
(AC+H)−(AC) −25.07
Stiffness (min: 0; max: 8)
AC+H n=127 n=124
5.06 (1.51) 3.22 (1.74) −1.83 (1.73) −34.74 (35.00) <0.0001
AC n=127 n=107
5.10 (1.42) 4.31 (1.56) −0.71 (1.57) −10.42 (37.42)
(AC+H)−(AC) −24.32
Physical function (min: 0; max: 68)
AC+H n=127 n=124
39.54 (9.27) 24.26 (12.95) −15.04 (12.29) −37.82 (31.44) <0.0001
AC n=127 n=107
40.20 (9.26) 33.87 (13.88) −5.85 (11.18) −14.52 (30.39)
(AC+H)−(AC) −23.30
SF-36§, mean (S.D.)
Aggregate physical component (min: 2; max: 76)
AC+H n=127 n=124
28.33 (6.60) 33.24 (10.16) 4.88 (9.78) 20.31 (37.43) <0.0001
AC n=126 n=107
28.18 (7.78) 27.78 (8.90) −0.40 (7.22) 1.07 (29.10)
(AC+H)−(AC) 19.24
Aggregate mental component (min: −2; max: 81)
AC+H n=127 n=124
51.74 (11.83) 55.29 (10.45) 3.32 (12.06) 11.53 (33.80) 0.0939
AC n=126 n=107
49.91 (11.82) 52.65 (11.56) 1.55 (10.55) 5.40 (23.11)
(AC+H)−(AC) 6.13
HUI3\ (min: −0.36; max 1), mean (S.D.)
AC+H n=123 n=122
0.50 (0.22) 0.63 (0.25) 0.13 (0.23) n/a <0.0001
AC n=126 n=107
0.46 (0.24) 0.51 (0.28) 0.03 (0.22) n/a
(AC+H) – (AC) 0.10
*Due to differences in sample size from baseline to month 12 computation of change (Month 12−Baseline) was calculated for patients with
both baseline and termination values.
†P-value results from Model 1 adjusting for design variables. The results were similar for model 2 adjusting for design variables and
potentially clinically important differences at baseline
‡The higher the score, the worse the problem
§The higher the score, the better the health perception
\The higher the score, the better the overall health utility
n/a denotes not applicable. Because HUI3 is an interval scale, percent improvements are not useful and indeed distort the magnitude of
change.
WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; AC+H=Appropriate Care+hylan G-F 20; AC=Appropriate
Care; SF-36=Short Form 36; HUI3=Health Utilities Index 3.The data reported that inclusion of hylan G-F 20 in an
appropriate care treatment regimen resulted in a meaning-
ful decrease in the utilization of other treatments for knee
OA. These decreases were statistically significant with
respect to the utilization of steroid injections, oral NSAID
therapy and ‘other’ medications for knee OA. Patients in
the AC+H group also received fewer arthroscopies and
fewer total knee replacements, but the difference was not
compared statistically.
Overall the safety data collected and analysed in this trial
confirm that patients treated in different ways are likely toexperience different patterns of side effects. Patients in the
AC+H group experienced some discomfort associated with
the intraarticular procedure. The 15 local adverse events
categorized as remotely, possibly or probably attributed to
hylan G-F 20 out of a total of approximately 700 hylan G-F
20 injections represents a rate of approximately 2%, similar
to that observed in other trials24. However, the hylan G-F
20 treated patients also had a clinically meaningful
decrease in both the number and severity of GI side effects
related to appropriate care and the need for medication to
treat GI side effects. Furthermore based on the patients’
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516 J.-P. Raynauld et al.: Effectiveness of hylan G-F 20 for knee OAglobal evaluation of side effects, it would appear that the
patients in the AC+H group judged themselves to have
experienced additional benefits by virtue of having en-
countered fewer side effects. These data suggest that a
management strategy, which includes hylan G-F 20 may
result in important safety gains, principally by reducing GI
events and the necessity for their treatment with GI medi-
cations. It should be noted that COX-2 selective inhibitors
were not available during the trial.
Although viscosupplementation with hylan G-F 20 is a
local treatment which was only used to treat knee OA in this
trial, the AC+H group experienced significantly better
improvements in global evaluations measuring overall OA,
and overall health, and in HRQOL instruments which reflect
the health status of the whole patient. This is particularly
surprising considering that in the AC+H group 68% of
patients had OA in some joint other than the knee and 49%
of patients scored their OA in all joints as poor or very poor
at baseline (Table I). These ‘whole patient’ improvements
probably reflect the fact that for the patients in this trial the
knee was their most symptomatic musculoskeletal prob-
lem, and was therefore a major determinant of their pain,
disability and HRQOL. It is not uncommon in OA patients
for one or two joints to be the primary source of the
patient’s disability25. Similar improvements in HRQOL are
observed after surgical treatments for knee OA such as
knee replacement26.
In keeping with the study’s pragmatic design, the X-ray
grade used to determine study inclusion was that scored by
the investigator entering the patient, and based on their
best clinical judgement and the radiologist report. The
investigator was not asked to provide a grade, but to
determine that the patient had OA that was not Grade IV.
Hence one radiologist will possibly provide a different rating
than the impression of 14 investigators who were not asked
to provide a grade. Because the authors were sensitive to
potential differences between investigators and to the
prevalence of ‘borderline’ scores, central grading was per-
formed by a trained radiologist. This was done after the
patients were entered and used only in the analyses.
Patients judged to have Grade IV X-ray by central scoring
were not asked to leave the trial.
Grade IV OA of the study knee was an exclusion
criterion, because those patients would be more likely to
receive surgery, and the intention was to avoid having
surgery dominate the cost results. Despite this exclusion
criterion, approximately 20–30% of patients in the study
were judged by a central radiologist to have grade IV OA. It
is not surprising that the grading provided by the site
investigators and central radiologist differed for some
patients, as the difference between grade level III and IV is
subtle. The effectiveness of hylan G-F 20 is not expected to
differ significantly for the two grade levels27. Patients with
grade IV OA are also indicative of real world practice. To
address the imbalance in X-ray grades between the two
treatment groups, the analyses adjusted for Grade IV OA
as a covariate; however, this did not change any results.
The demographics of aging populations make OA a
particularly challenging medical and socioeconomic prob-
lem28. There is therefore a growing pool of patients
with symptomatic knee OA who must be managed for
many years, and in whom it is desirable to delay knee
replacement for as long as possible. Currently the only
treatments widely available for such patients are prescrip-
tion NSAIDS or analgesics, intraarticular steroid injections,
topical agents, and arthroscopic lavage and debridement.
All of these available modalities have drawbacks or signifi-cant side effects. The data presented here indicate that the
provision to patients with knee OA of viscosupplementation
with hylan G-F 20 within an appropriate care treatment
regimen provides benefits in the knee, overall health and
health related quality of life at reduced levels of co-therapy
and systemic adverse reactions.Acknowledgments
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